Overview

Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The primary aim is to observe the haemostatic efficacy of NovoSeven® treatment during routine practice in German clinics. The observational study observes patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX, acquired haemophilia, congenital FVII deficiency, or Glanzmann's thrombasthenia who have received at least one dose of NovoSeven® for treatment of a bleeding episode or for the prevention of a bleeding when undergoing surgery or an invasive procedure.
Details
Lead Sponsor:
Novo Nordisk A/S